
Laboratoires (ALEMG) | Financial Analysis & Statements
Laboratoires Euromedis S.A. | Small-cap | Healthcare
Laboratoires Euromedis S.A. | Small-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
38.8M
Total Liabilities
22.3M
Shareholders Equity
16.5M
Debt to Equity
1.35
Cash Flow Metrics
Revenue & Profitability Trend
Laboratoires Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 36.2M | 34.0M | 54.2M | 111.9M | 193.4M |
Cost of Goods Sold | 34.3M | 33.9M | 35.4M | 78.4M | 129.3M |
Gross Profit | 1.9M | 181.7K | 18.7M | 33.5M | 64.2M |
Gross Margin % | 5.3% | 0.5% | 34.6% | 29.9% | 33.2% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | - | 18.1M | 17.0M |
Other Operating Expenses | 1.2M | 3.2M | 19.6M | 22.9M | 24.2M |
Total Operating Expenses | 1.2M | 3.2M | 19.6M | 41.0M | 41.2M |
Operating Income | 1.3M | -4.3M | -5.4M | 3.7M | 28.7M |
Operating Margin % | 3.6% | -12.5% | -10.0% | 3.3% | 14.8% |
Non-Operating Items | |||||
Interest Income | 590.0K | 27.7M | 18.0K | 43.0K | 177.0K |
Interest Expense | 502.1K | 359.8K | 365.0K | 345.0K | 457.0K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 376.7K | 21.7M | -6.0M | 2.5M | 28.5M |
Income Tax | -3.9K | 269.0K | -41.0K | 210.0K | 5.5M |
Effective Tax Rate % | -1.0% | 1.2% | 0.0% | 8.4% | 19.4% |
Net Income | -6.1M | 13.1M | -5.9M | 2.3M | 22.9M |
Net Margin % | -16.9% | 38.5% | -11.0% | 2.1% | 11.8% |
Key Metrics | |||||
EBITDA | 2.0M | 23.5M | -4.2M | 5.1M | 34.0M |
EPS (Basic) | - | €4.60 | €-1.97 | €0.75 | €7.53 |
EPS (Diluted) | - | €4.60 | €-1.97 | €0.63 | €6.33 |
Basic Shares Outstanding | - | 2849001 | 3010488 | 3010488 | 3008738 |
Diluted Shares Outstanding | - | 2849001 | 3010488 | 3010488 | 3008738 |
Income Statement Trend
Laboratoires Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 15.2M | 18.8M | 26.8M | 31.9M | 15.7M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 7.7M | 8.5M | 8.8M | 14.0M | 24.1M |
Inventory | 11.9M | 9.6M | 12.6M | 11.8M | 25.7M |
Other Current Assets | - | - | - | - | 2.0K |
Total Current Assets | 37.6M | 39.3M | 51.9M | 64.4M | 83.3M |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.4M | 287.1K | 8.2M | 7.5M | 9.8M |
Goodwill | 189.8K | 4.2M | 5.2M | 5.4M | 7.6M |
Intangible Assets | 189.8K | 4.2M | 87.0K | 142.0K | 133.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | -355 | 2.5K | - | - | - |
Total Non-Current Assets | 1.1M | 7.0M | 8.0M | 8.3M | 9.3M |
Total Assets | 38.8M | 46.3M | 59.9M | 72.7M | 92.6M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 9.5M | 7.8M | 7.3M | 10.5M | 20.7M |
Short-term Debt | - | - | 3.0K | 541.0K | 1.3M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | 33.0K | 213.0K | 13.0K |
Total Current Liabilities | 10.7M | 8.9M | 9.5M | 13.7M | 34.1M |
Non-Current Liabilities | |||||
Long-term Debt | 8.0M | 10.0M | 12.8M | 15.0M | 16.5M |
Deferred Tax Liabilities | - | - | 332.0K | 349.0K | 300.0K |
Other Non-Current Liabilities | 1.6M | 1.5M | 2.0K | 3.0K | - |
Total Non-Current Liabilities | 11.6M | 14.8M | 15.4M | 17.8M | 19.6M |
Total Liabilities | 22.3M | 23.7M | 25.0M | 31.5M | 53.7M |
Equity | |||||
Common Stock | 5.7M | 5.7M | 6.0M | 6.0M | 6.0M |
Retained Earnings | -2.2M | 4.2M | -5.9M | 2.3M | 22.7M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 16.5M | 22.6M | 34.9M | 41.2M | 38.9M |
Key Metrics | |||||
Total Debt | 8.0M | 10.0M | 12.8M | 15.5M | 17.8M |
Working Capital | 27.0M | 30.4M | 42.3M | 50.7M | 49.2M |
Balance Sheet Composition
Laboratoires Cash Flow Statement From 2017 to 2022
Metric | 2022 | 2021 | 2020 | 2019 | 2017 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -5.9M | 2.3M | 22.9M | -3.6M | -134.0K |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 0 | 0 | 0 | 804.0K | -883.0K |
Operating Cash Flow | -5.9M | 2.4M | 22.9M | -2.7M | -1.1M |
Investing Activities | |||||
Capital Expenditures | -1.0M | -1.4M | -653.0K | -1.4M | 8.0K |
Acquisitions | - | - | - | - | -341.0K |
Investment Purchases | - | - | - | - | -60.0K |
Investment Sales | 22.0K | 434.0K | 61.0K | - | - |
Investing Cash Flow | -1.1M | -1.1M | -592.0K | -1.2M | -734.0K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | 36.0K |
Dividends Paid | - | - | - | - | -269.0K |
Debt Issuance | - | - | 20.0M | 11.8M | 1.1M |
Debt Repayment | -2.2M | -1.3M | -10.6M | -8.4M | -1.0M |
Financing Cash Flow | -2.1M | -1.3M | 9.4M | 3.4M | -52.0K |
Free Cash Flow | -2.1M | 17.4M | 12.8M | -2.3M | -232.0K |
Net Change in Cash | -9.1M | -34.0K | 31.7M | -490.0K | -1.9M |
Cash Flow Trend
Laboratoires Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
28.20
Forward P/E
10.58
Price to Book
0.73
Price to Sales
0.33
PEG Ratio
10.58
Profitability Ratios
Profit Margin
-16.78%
Operating Margin
5.27%
Return on Equity
-31.26%
Return on Assets
0.58%
Financial Health
Current Ratio
2.97
Debt to Equity
48.76
Beta
0.28
Per Share Data
EPS (TTM)
€0.15
Book Value per Share
€5.80
Revenue per Share
€12.64
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
alemg | 12.1M | 28.20 | 0.73 | -31.26% | -16.78% | 48.76 |
Bastide le Confort | 207.6M | 24.48 | 2.77 | 10.46% | 0.32% | 541.81 |
Metrics In Balance | 790.3K | - | 0.01 | -0.45% | -17,317.00% | - |
EssilorLuxottica | 127.0B | 52.88 | 3.31 | 6.44% | 8.74% | 36.58 |
Sartorius Stedim | 17.6B | 76.84 | 4.40 | 5.69% | 7.78% | 73.51 |
bioMérieux S.A | 15.0B | 35.00 | 3.57 | 10.68% | 10.86% | 11.65 |
Financial data is updated regularly. All figures are in the company's reporting currency.